Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong

BACKGROUND AND OBJECTIVES: Type 2 diabetes mellitus (T2DM) patients with Coronavirus Disease 2019 (COVID-19) have poorer prognosis. Inconclusive evidence suggested dipeptidyl peptidase-4 inhibitors (DPP4i) might reduce inflammation and prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Carlos K.H., Lui, David T.W., Lui, Angel Y.C., Kwok, Ashley C.Y., Low, Marshall C.H., Lau, Kristy T.K., Au, Ivan C.H., Xiong, Xi, Chung, Matthew S.H., Lau, Eric H.Y., Cowling, Benjamin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632053/
https://www.ncbi.nlm.nih.gov/pubmed/34863934
http://dx.doi.org/10.1016/j.diabet.2021.101307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632053/
https://www.ncbi.nlm.nih.gov/pubmed/34863934
http://dx.doi.org/10.1016/j.diabet.2021.101307

Ejemplares similares